Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population.

Antiviral therapy - 1 Jan 2007

Fung James, Lai Ching-Lung, Yuen John Chi-hang, Wong Danny Ka-Ho, Tanaka Yasuhito, Mizokami Masashi, Yuen Man-Fung

Abstract excerpt

AIM: To determine differences in Chinese patients treated with adefovir (ADV) monotherapy or ADV in combination with lamivudine (3TC) after development of resistance to 3TC, with respect to biochemical improvement, HBV DNA suppression and development of subsequent ADV resistance. METHODS: All hepatitis B patients with 3TC resistance treated with ADV for 3 months or more at our centre were included, and monitored...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Alanine Transaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Viral

Share to Hepatitis B, Chronic

Share to Hong Kong

Share to Lamivudine

Share to Organophosphonates

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 17503746

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population.PMID 17503746Read ↗

Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Virological response to adefovir monotherapy and the risk of adefovir resistance.Semantic proximity Read ↗

[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].Semantic proximity Read ↗

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.Semantic proximity Read ↗

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.Semantic proximity Read ↗

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.Semantic proximity Read ↗

Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.Semantic proximity Read ↗

Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.Semantic proximity Read ↗

Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.Semantic proximity Read ↗

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.